BioSyent Pharma Acquires Exclusive Rights For Cysview(R) In Canada
August 19, 2015 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - Aug. 19, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announced today that its subsidiary BioSyent Pharma Inc. has signed an agreement with...
BioSyent Releases First Six Months 2015 Results-Six Month Sales Up 25%; Pharma Sales Up 25%; EBITDA Up 31%; Net Income Up 30%; Return on Equity 40%
August 12, 2015 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - Aug. 12, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its Second Quarter (Q2 2015) and first half financial results for...
CORRECTION FROM SOURCE: BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%
May 13, 2015 16:21 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - May 13, 2015) - A correction from source is being issued with respect to the BioSyent Inc. release that was disseminated May 13, 2015 at 08:00 ET. The...
BioSyent Releases First Quarter 2015 Results - Sales Up 35%; Pharma Sales Up 38%; Ebitda up 92%; Diluted EPS $0.07, Up 75%; Net Income Up 88%
May 13, 2015 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - May 13, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its First Quarter (Q1 2015) financial results. Key highlights...
BioSyent to Present at the 2015 Bloom Burton & Co. Healthcare Investor Conference
May 01, 2015 16:01 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - May 1, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that CEO René Goehrum will be making a presentation at the 2015...
BioSyent Comments on Recent Market Activity
April 10, 2015 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - April 10, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) wishes to comment on the unusual recent market activity in its stock. The Company advises...
BioSyent Releases Q4 and Full Year 2014 Results - Full Year Sales Up 57%; Pharma Sales Up 63%; Net Income Up 64%; Diluted EPS $0.22 Up 69%; Cash and Short-Term Investments $8.0 Million Up 82%
February 25, 2015 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - Feb. 25, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its Fiscal 2014 and Fourth Quarter (Q4 2014) financial results....
BioSyent Pharma Announces the Canadian Launch of the First of 3 New Products Using the Patented Aguettant System(R)
February 03, 2015 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - Feb. 3, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of...
BioSyent Pharma Launches New Proktis-M(R) Suppositories
November 24, 2014 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - Nov. 24, 2014) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of...
BioSyent Releases Q3 and Nine Month Results-Q3 Sales Increase 56%, Net Income Up 64%; Nine Month Sales Up 62%, Net Income Up 75%
October 20, 2014 08:00 ET
|
BioSyent Inc.
TORONTO, ONTARIO--(Marketwired - Oct. 20, 2014) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its Third Quarter (Q3 2014) and nine months financial results for...